MSD Continues to Foster Vibrant, Creative Workspaces as it Launches New Zurich Hub

The new Innovation and Development Hub in Zürich is focused on accelerating research, data and commercialization of our medicines and vaccines. The new office will be staffed by teams working in strategic and operational roles in medical affairs, clinical development, access and marketing operations functions.

A blog by Klaus Beck, Vice President, Medical Affairs, MSD

"Today we are introducing a new blog series about the MSD's new Innovation and Development Hub in Zurich. In the series, you will hear from leaders who are part of the new hub. Our first blog comes from Klaus Beck, one of the leaders of the project."

Klaus Beck, VP MSD Global Medical Affairs EMEAC, MSD Switzerland

While we all come from widely diverse backgrounds, cultures, ethnicities, every person at MSD shares one thing in common: we are all driven by our company’s mission, to save and improve lives. At the heart of this mission is a steadfast, unparalleled commitment to science and innovation. As we accelerate the establishment of our new global innovation and development hub in Zurich, my pride in our company continues to grow. It’s rewarding and fulfilling to be part of an initiative that will have a true impact on global health.

Learn more


A blog post by Laura Luchini: Continuing our momentum in Zurich

“Coming together is a beginning; keeping together is progress; working together is success.” This quote from American businessman Henry Ford has long inspired me.

For the past 25 years, I’ve taken my career in many directions – all in a quest to enhance my experiences, broaden my skillsets and deepen my connections. Today, I’m proud to be in a role that means a lot to me: I am coordinating the set-up of MSD’s new global innovation and development hub in Zurich. The new Hub is yet another example of MSD’s steadfast, unparalleled commitment to science, and supports our mission of saving and improving lives. I’m enormously honored to be part of it.

Learn more


CH-NON-00885, 11/20